eligibility_summary
Eligible: adults with unresectable locally advanced/metastatic solid tumors lacking effective/tolerable standard therapy, ECOG 0–1, adequate organ function by labs, agree to highly effective contraception (WOCBP and nonsterile men). Exclude: active leptomeningeal disease or uncontrolled brain mets, active/relapsing autoimmune disease, other malignancy ≤3y (except index/curatively treated local), severe mAb hypersensitivity, untreated HBV/carriers, known HIV.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: Phase 1a/1b (dose escalation/expansion), withdrawn. Interventions: 1) BGB-B167 (IV). Type: investigational anticancer drug (immunotherapy). Mechanism: not specified in the registry entry. 2) Tislelizumab (BGB-A317, IV). Type: humanized IgG4 monoclonal antibody, immune checkpoint inhibitor. Mechanism: binds PD‑1 and blocks PD‑1/PD‑L1 signaling to restore T‑cell antitumor activity. Targets/cells/pathways: Tislelizumab targets PD‑1 on activated T cells, relieving inhibitory signaling and enhancing cytotoxic T‑cell function within the tumor microenvironment. BGB‑B167’s specific molecular target/pathway is not disclosed here, the combination is intended to augment T‑cell–mediated antitumor immunity.